论文部分内容阅读
帕金森病治疗药物Stalevo为恩他卡朋、卡比多巴和左旋多巴组成的复方制剂。2010年3月31日,FDA曾发布消息提醒医护人员及患者Stalevo可能会增大使用者罹患前列腺癌的风险,FDA表示将会针对此问题及时通告该药的安全性信息。9月2日,FDA再次就该药物的安全性发布新闻称,一些临床试验数据审查结果显示,与Sinemet(卡比多巴/左旋多巴)相比,Stalevo可能会增加心血管风险(心力衰竭、卒中、心血管死亡)。
Parkinson’s disease treatment Stalevo is a combination of entacapone, carbidopa and levodopa. On March 31, 2010, the FDA released news reminding healthcare workers and patients that Stalevo may increase their risk of prostate cancer. The FDA said it will promptly notify the safety information about the drug. On September 2, the FDA released news of the drug’s safety once again. According to the results of some clinical trial data, Stalevo may increase cardiovascular risk compared with Sinemet (cardibault / levodopa) (heart failure , Stroke, cardiovascular death).